Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine.

Leroux-Roels, Isabel; Bruhwyler, Jacques; Stergiou, Lilli; Sumeray, Mark; Joye, Jasper; Maes, Cathy; Lambert, Paul-Henri; Leroux-Roels, Geert

Leroux-Roels, Isabel; Bruhwyler, Jacques; Stergiou, Lilli; Sumeray, Mark; Joye, Jasper; Maes, Cathy; Lambert, Paul-Henri; Leroux-Roels, Geert.

Afiliação

Leroux-Roels I; Center for Vaccinology (CEVAC), Ghent University Hospital, Corneel Heymanslaan 10, B-9000 Ghent, Belgium.
Bruhwyler J; Expert Clinical Services Organization (ECSOR) sa/nv, Rue de la Station 78, B-1630 Linkebeek, Belgium.
Stergiou L; Virometix AG, Wagistrasse 14, 8952 Schlieren, Switzerland.
Sumeray M; Virometix AG, Wagistrasse 14, 8952 Schlieren, Switzerland.
Joye J; Center for Vaccinology (CEVAC), Ghent University Hospital, Corneel Heymanslaan 10, B-9000 Ghent, Belgium.
Maes C; Center for Vaccinology (CEVAC), Ghent University Hospital, Corneel Heymanslaan 10, B-9000 Ghent, Belgium.
Lambert PH; Department of Paediatrics, Gynecology and Obstetrics, University of Geneva, Rue du Général Dufour 24, 1211 Geneva, Switzerland.
Leroux-Roels G; Center for Vaccinology (CEVAC), Ghent University Hospital, Corneel Heymanslaan 10, B-9000 Ghent, Belgium.

Vaccines (Basel) ; 11(2)2023 Feb 06.

Article em En | MEDLINE | ID: mdl-36851245